Indaptus Corp (INDP) Company Cash Funds

The cash on hand metric on this GURU.Markets platform chart, where the value 0.03 serves as the baseline indicator, correlates with the data preparation for the Decoy platform. The tool is based on a strategy of global immunopharma market capture through the activation of innate immunity. The safety of such developments relies on strict medical logistics and precision control of supply chains for Indaptus Therapeutics (INDP).
Analytical breakdowns and data insights for company Indaptus (INDP)

Minimizing fundamental risks requires strict control over the issuer's liquidity. This indicator tracks the daily cash balance, allowing for an accurate calculation of the capital burn rate. For Indaptus Therapeutics (INDP), this resource is critical when funding costly immunotherapy trials at oncology centers. By analyzing the cash structure, an investor determines the company's margin of safety in the face of market shocks.